Other Major and Mild Neurocognitive Disorders: Parkinson Disease, Atypical Parkinsonism, and Traumatic Brain Injury Types

  • Ana Hategan
  • James A. Bourgeois
  • Tracy Cheng
  • Julie Young


Although Parkinson disease has long been considered predominantly a motor disease, it is often associated with cognitive and other neuropsychiatric symptoms, which contribute significantly to the morbidity and mortality of patients with this condition. Major or mild neurocognitive disorder due to Parkinson disease has a unique clinical profile and neuropathology, distinct from the neurocognitive disorder due to Alzheimer disease. However, a variety of neurological disorders can present with atypical parkinsonism, in which symptoms are caused not only by cell loss in the substantia nigra (the brain area most affected in Parkinson disease) but also by degeneration of cells in other brain regions that normally contain dopamine receptors (e.g., striatum). They can present with symptoms and signs similar to Parkinson disease, including resting tremor, slowed movement, rigidity, gait difficulty, and postural instability, but in addition have symptoms and signs that are not typically present in Parkinson disease. Forms of atypical parkinsonism that have been associated with neurocognitive disorder include progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, and vascular parkinsonism. Neurocognitive disorder with Lewy bodies is often included in this group of atypical parkinsonian syndromes (discussed elsewhere in more detail). Another etiology presented in this section is traumatic brain injury, in which the brain injury is associated with cognitive impairment occurring within the appropriate time period. This review outlines the clinical diagnostic criteria, differential diagnosis, and management for these types of neurocognitive disorders.


Major or mild neurocognitive disorder due to Parkinson disease Parkinson disease dementia Atypical parkinsonism Progressive supranuclear palsy Multiple system atrophy Corticobasal degeneration Lewy body disease Traumatic brain injury 


  1. 1.
    Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901–5.CrossRefGoogle Scholar
  2. 2.
    Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016;188(16):1157–65.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU. The differential diagnosis and treatment of atypical parkinsonism. Dtsch Arztebl Int. 2016;113(5):61–9.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Klockgether T. Parkinson’s disease: clinical aspects. Cell Tissue Res. 2004;318:115–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Helmich RC, Hallett M, Deuschl G, Toni I, Bloem BR. Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain. 2012;135(11):3206–26.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pellicano C, Benincasa D, Pisani V, Buttarelli FR, Giovannelli M, Pontieri FE. Prodromal non-motor symptoms of Parkinson’s disease. Neuropsychiatr Dis Treat. 2007;3(1):145–52.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Tosto G, Monsell SE, Hawes SE, Mayeux R. Pattern of extrapyramidal signs in Alzheimer’s disease. J Neurol. 2015;262(11):2548–56.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Bhatia KP, Stamelou M. Nonmotor features in atypical parkinsonism. Int Rev Neurobiol. 2017;134:1285–301.CrossRefPubMedGoogle Scholar
  10. 10.
    Bayulkem K, Lopez G. Clinical approach to nonmotor sensory fluctuations in Parkinson’s disease. J Neurol Sci. 2011;310(1–2):82–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Simuni T, Sethi K. Nonmotor manifestations of Parkinson’s disease. Ann Neurol. 2008;64(Suppl 2):S65–80.PubMedGoogle Scholar
  12. 12.
    Aarsland D, Kramberger MG. Neuropsychiatric symptoms in Parkinson’s disease. J Parkinsons Dis. 2015;5(3):659–67.CrossRefPubMedGoogle Scholar
  13. 13.
    Lemke MR, Fuchs G, Gemende I, et al. Depression and Parkinson’s disease. J Neurol. 2004;251(Suppl 6):VI/24–7.Google Scholar
  14. 14.
    Jacob E, Gatto N, Thompson A, Bordelon Y, Ritz B. Occurrence of depression and anxiety prior to Parkinson’s disease. Parkinsonism Relat Disord. 2010;16(9):576–81.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chaudhuri KR. Nocturnal symptom complex in PD and its management. Neurology. 2003;61(Suppl 3):S17–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Roychowdhury S, Forsyth DR. Sleep disturbance in Parkinson disease. J Clin Gerontol Geriatr. 2012;3(2):53–61.CrossRefGoogle Scholar
  17. 17.
    Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behavior disorder: demographic, clinical and laboratory findings in 93 cases. Brain. 2000;123:388–93.CrossRefGoogle Scholar
  18. 18.
    Zhang J, Xu C-Y, Liu J. Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson’s disease. BMC Neurol. 2017;17:23.–017–0795–4.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996–1002.CrossRefPubMedGoogle Scholar
  20. 20.
    Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(11):924–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Marsh L. Depression and Parkinson’s disease: current knowledge. Curr Neurol Neurosci Rep. 2013;13(12):409.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Richard IH, McDermott MP, Kurlan R, et al. SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78(16):1229–36.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Combs BL, Cox AG. Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin. Neuropsychiatr Dis Treat. 2017;13:737–44.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–4.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Marek K, Innis R, Van Dyck C, et al. [123I]-beta-CIT-SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology. 2001;57:2089–94.CrossRefPubMedGoogle Scholar
  26. 26.
    Tong J, Wong H, Guttman M, et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson’s disease and progressive supranuclear palsy: a comparative investigation. Brain. 2010;133(Pt 1):172–88.CrossRefPubMedGoogle Scholar
  27. 27.
    Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56(12):1702–6.CrossRefPubMedGoogle Scholar
  28. 28.
    McFarland NR. Diagnostic approach to atypical parkinsonian syndromes. Continuum (Minneap Minn). 2016;22(4 Movement Disorders):1117–42.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A, Turner K, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry. 2007;78(5):465–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Lamb R, Rohrer JD, Lees AJ, Morris HR. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr Treat Options Neurol. 2016;18(9):42.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson’s disease. Cochrane Database Syst Rev. 2009;(4):CD006661.Google Scholar
  32. 32.
    Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf. 2009;32(6):475–88.CrossRefPubMedGoogle Scholar
  33. 33.
    Seeberger LC, Hauser RA. Carbidopa levodopa enteral suspension. Expert Opin Pharmacother. 2015;16(18):2807–17.CrossRefPubMedGoogle Scholar
  34. 34.
    Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(5):402–11.CrossRefPubMedGoogle Scholar
  35. 35.
    Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–64.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Stamelou M, de Silva R, Arias-Carrión O, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain. 2010;133(Pt 6):1578–90.CrossRefPubMedGoogle Scholar
  37. 37.
    Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998;64(2):184–9.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Gerstenecker A, Duff K, Mast B, Litvan I. ENGENE-PSP Study Group. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res. 2013;210(3):1205–10.CrossRefPubMedGoogle Scholar
  39. 39.
    Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. Corticobasal degeneration. Lancet Neurol. 2004;3:736–43.CrossRefPubMedGoogle Scholar
  40. 40.
    Cassidy JD, Carroll LJ, Peloso PM, et al. Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med. 2004;(43 Suppl):28–60.CrossRefGoogle Scholar
  41. 41.
    McInnes K, Friesen CL, MacKenzie DE, Westwood DA, Boe SG. Mild traumatic brain injury (mTBI) and chronic cognitive impairment: a scoping review. PLoS One. 2017;12(4):e0174847.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Starkstein SE, Jorge R. Dementia after traumatic brain injury. Int Psychogeriatr. 2005;17(Suppl 1):S93–107.CrossRefPubMedGoogle Scholar
  43. 43.
    Bazarian JJ, Atabaki S. Predicting postconcussion syndrome after minor traumatic brain injury. Acad Emerg Med. 2001;8(8):788–95.CrossRefPubMedGoogle Scholar
  44. 44.
    Rutherford WH, Merrett JD, McDonald JR. Symptoms at one year following concussion from minor head injuries. Injury. 1979;10(3):225–30.CrossRefPubMedGoogle Scholar
  45. 45.
    Mendez MF. What is the relationship of traumatic brain injury to dementia? J Alzheimers Dis. 2017;57(3):667–81.CrossRefPubMedGoogle Scholar
  46. 46.
    Frankel J, Marwitz J, Cifu D, Kreutzer J, Englander J, Rosenthal M. A follow-up study of older adults with traumatic brain injury: taking into account decreasing length of stay. Arch Phys Med Rehabil. 2006;87(1):57–62.CrossRefPubMedGoogle Scholar
  47. 47.
    Filer W, Harris M. Falls and traumatic brain injury among older adults. N C Med J. 2015;76(2):111–4.PubMedGoogle Scholar
  48. 48.
    Faul M, Xu L, Wald MM, Coronado VG, U.S. Department of Health and Human Services, editors. Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths 2002–2006. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010. Accessed 11 Sept 2017.Google Scholar
  49. 49.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.CrossRefGoogle Scholar
  50. 50.
    Teasdale G, Jennet B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2:81–4.CrossRefPubMedGoogle Scholar
  51. 51.
    King N. A systematic review of age and gender factors in prolonged post-concussion symptoms after mild head injury. Brain Inj. 2014;28(13–14):1639–45.CrossRefPubMedGoogle Scholar
  52. 52.
    Hawley C, Sakr M, Scapinello S, et al. Traumatic brain injuries in older adults—6 years of data for one UK trauma centre: retrospective analysis of prospectively collected data. Emerg Med J. 2017;34:509–16.CrossRefPubMedGoogle Scholar
  53. 53.
    Malec JF, Brown AW, Leibson CL, et al. The Mayo classification system for traumatic brain injury severity. J Neurotrauma. 2007;24(9):1417–24.CrossRefPubMedGoogle Scholar
  54. 54.
    Menzel JC. Depression in the elderly after traumatic brain injury: a systematic review. Brain Inj. 2008;22(5):375–80.CrossRefPubMedGoogle Scholar
  55. 55.
    Bombardier CH, Fann JR, Temkin NR, Esselman PC, Barber J, Dikmen SS. Rates of major depressive disorder and clinical outcomes following traumatic brain injury. JAMA. 2010;303(19):1938–45.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ana Hategan
    • 1
  • James A. Bourgeois
    • 2
    • 3
  • Tracy Cheng
    • 4
  • Julie Young
    • 5
  1. 1.Department of Psychiatry and Behavioural NeurosciencesMcMaster UniversityHamiltonCanada
  2. 2.Department of PsychiatryBaylor Scott and White Health Central Texas DivisionDallasUSA
  3. 3.Department of PsychiatryTexas A&M University Health Science Center, College of MedicineTempleCanada
  4. 4.St. Joseph’s Healthcare Hamilton, McMaster UniversityHamiltonUSA
  5. 5.Mercy San Juan Medical CenterFarmingtonUSA

Personalised recommendations